Risk of oxalate nephropathy with the use of cyanide antidote hydroxocobalamin in critically ill burn patients

Intensive Care Med. 2016 Jun;42(6):1080-1. doi: 10.1007/s00134-016-4252-4. Epub 2016 Feb 18.

Matthieu Legrand^{1

2

3}, Thibault Michel⁴, Michel Daudon^{5

6}, Mourad Benyamina⁴, Axelle Ferry⁴, Sabri Soussi⁴, Véronique Maurel⁴, Maïte Chaussard⁴, Marc Chaouat^{7

8}, Maurice Mimoun^{7

8}, Jérôme Verine^{7

9}, Vincent Mallet¹⁰, Alexandre Mebazaa^{4

7

11}; PRONOBURN Study Group

¹ Department of Anaesthesiology and Critical Care and Burn Unit, Hôpital St-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010, Paris, France. [email protected].
² University of Paris Diderot, Paris, France. [email protected].
³ U-942 INSERM, 75475, Paris, France. [email protected].
⁴ Department of Anaesthesiology and Critical Care and Burn Unit, Hôpital St-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010, Paris, France.
⁵ APHP, Laboratoire des Lithiases, Service d'Explorations Fonctionnelles Multidisciplinaires, Hôpital Tenon, 75020, Paris, France.
⁶ Sorbonne Universités, UPMC, INSERM UMR S 1155, 75020, Paris, France.
⁷ University of Paris Diderot, Paris, France.
⁸ Plastic Surgery, Hôpital St-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010, Paris, France.
⁹ APHP, Department of Pathology, Hôpital St-Louis, Paris, France.
¹⁰ Université Paris Descartes, Institut Pasteur, Unité Mixte de Service 020, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Cochin Port Royal, Service d'Hépatologie, Paris, France.
¹¹ U-942 INSERM, 75475, Paris, France.

No abstract available

Publication types